A phase 2, open label, multicenter, single arm study of tocilizumab on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia (TOCIVID-19 trial): Statistical analysis plan

Background: Tocilizumab, an IL-6 receptor antagonist, was suggested as a possible treatment of severe or critical COVID-19 pneumonia in a small Chinese study. The TOCIVID-19 trial evaluates efficacy and tolerability of tocilizumab in the treatment of patients with severe or critical COVID-19 pneumon...

Full description

Bibliographic Details

Published in:	Contemporary Clinical Trials Communications
Main Authors:	Paolo Chiodini, Laura Arenare, Maria Carmela Piccirillo, Francesco Perrone, Ciro Gallo
Format:	Article
Language:	English
Published:	Elsevier 2020-12-01
Subjects:	Statistical analysis plan COVID-19 pneumonia Tocilizumab Phase 2 trial
Online Access:	http://www.sciencedirect.com/science/article/pii/S2451865420301496